NCT06435260View on ClinicalTrials.gov

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Camrelizumab+chemotherapy

"Chemotherapy combined with ICIs was started 5-7 days after the completion of radiotherapy:~AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles.~Camrelizumab: 200mg, iv, 30min, q3w, 4 cycles."

RADIATION

hypofractionated radiotherapy

Hypofractionated radiotherapy:PGTV=30Gy/5F(PTV≥25Gy/5F),

Trial Locations (1)

050011

RECRUITING

Fourth Hospital of Hebei Medical University, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER